1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Esophageal Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Esophageal Cancer Therapeutics Market, by Therapy Type
8.1.1. Chemotherapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Immunotherapy (PD-1/PD-L1, IO combinations)
8.1.2.1. Market Revenue and Forecast
8.1.3. Targeted Therapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Other Therapies (supportive/adjunct oncology drugs)
8.1.4.1. Market Revenue and Forecast
9.1. Esophageal Cancer Therapeutics Market, by Cancer Type
9.1.1. Esophageal Squamous Cell Carcinoma (ESCC)
9.1.1.1. Market Revenue and Forecast
9.1.2. Esophageal Adenocarcinoma (EAC)
9.1.2.1. Market Revenue and Forecast
10.1. Esophageal Cancer Therapeutics Market, by Stage of Disease
10.1.1. Locally Advanced/Resectable Disease
10.1.1.1. Market Revenue and Forecast
10.1.2. Neoadjuvant therapy
10.1.2.1. Market Revenue and Forecast
10.1.3. Adjuvant therapy
10.1.3.1. Market Revenue and Forecast
10.1.4. Metastatic/Advanced Disease
10.1.4.1. Market Revenue and Forecast
11.1. Esophageal Cancer Therapeutics Market, by End-User
11.1.1. Hospitals & Oncology Centers
11.1.1.1. Market Revenue and Forecast
11.1.2. Specialty Cancer Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic & Research Institutes
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type
12.1.2. Market Revenue and Forecast, by Cancer Type
12.1.3. Market Revenue and Forecast, by Stage of Disease
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type
12.1.5.2. Market Revenue and Forecast, by Cancer Type
12.1.5.3. Market Revenue and Forecast, by Stage of Disease
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type
12.1.6.2. Market Revenue and Forecast, by Cancer Type
12.1.6.3. Market Revenue and Forecast, by Stage of Disease
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type
12.2.2. Market Revenue and Forecast, by Cancer Type
12.2.3. Market Revenue and Forecast, by Stage of Disease
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type
12.2.5.2. Market Revenue and Forecast, by Cancer Type
12.2.5.3. Market Revenue and Forecast, by Stage of Disease
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type
12.2.6.2. Market Revenue and Forecast, by Cancer Type
12.2.6.3. Market Revenue and Forecast, by Stage of Disease
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type
12.2.7.2. Market Revenue and Forecast, by Cancer Type
12.2.7.3. Market Revenue and Forecast, by Stage of Disease
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type
12.2.8.2. Market Revenue and Forecast, by Cancer Type
12.2.8.3. Market Revenue and Forecast, by Stage of Disease
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type
12.3.2. Market Revenue and Forecast, by Cancer Type
12.3.3. Market Revenue and Forecast, by Stage of Disease
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type
12.3.5.2. Market Revenue and Forecast, by Cancer Type
12.3.5.3. Market Revenue and Forecast, by Stage of Disease
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type
12.3.6.2. Market Revenue and Forecast, by Cancer Type
12.3.6.3. Market Revenue and Forecast, by Stage of Disease
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type
12.3.7.2. Market Revenue and Forecast, by Cancer Type
12.3.7.3. Market Revenue and Forecast, by Stage of Disease
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type
12.3.8.2. Market Revenue and Forecast, by Cancer Type
12.3.8.3. Market Revenue and Forecast, by Stage of Disease
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type
12.4.2. Market Revenue and Forecast, by Cancer Type
12.4.3. Market Revenue and Forecast, by Stage of Disease
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type
12.4.5.2. Market Revenue and Forecast, by Cancer Type
12.4.5.3. Market Revenue and Forecast, by Stage of Disease
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type
12.4.6.2. Market Revenue and Forecast, by Cancer Type
12.4.6.3. Market Revenue and Forecast, by Stage of Disease
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type
12.4.7.2. Market Revenue and Forecast, by Cancer Type
12.4.7.3. Market Revenue and Forecast, by Stage of Disease
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type
12.4.8.2. Market Revenue and Forecast, by Cancer Type
12.4.8.3. Market Revenue and Forecast, by Stage of Disease
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type
12.5.2. Market Revenue and Forecast, by Cancer Type
12.5.3. Market Revenue and Forecast, by Stage of Disease
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type
12.5.5.2. Market Revenue and Forecast, by Cancer Type
12.5.5.3. Market Revenue and Forecast, by Stage of Disease
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type
12.5.6.2. Market Revenue and Forecast, by Cancer Type
12.5.6.3. Market Revenue and Forecast, by Stage of Disease
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. Bristol-Myers Squibb (BMS)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Merck & Co
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. F. Hoffmann-La Roche (Genentech)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. AstraZeneca
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Eli Lilly and Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. BeiGene
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Novartis AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Pfizer Inc
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sanofi
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Abbott
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
